每经AI快讯，步长制药（SH 603858，收盘价：16.74元）11月21日晚间发布公告称，截至本公告披露 日，公司及控股子公司已提供的担保总额为人民币约22.16亿元，占2024年末经审计的公司净资产的 21.69%。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 2024年1至12月份，步长制药的营业收入构成为：医药行业占比99.71%，其他业务占比0.29%。 截至发稿，步长制药市值为177亿元。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-218 山东步长制药股份有限公司 关于为公司控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 上海合璞医疗科技有限公司 | | --- | --- | --- | --- | | | 本次担保金额 | 13,000 万元 | | | 担保对象一 | 实际为其提供的担保余额 | 14,000 万元 | | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 □否 | □不适用：_________ | | 担保对象二 | 被担保人名称 | | 上海合璞医疗器械有限公司 | | | 本次担保金额 | 2,600 万元 | | | | 实际为其提供的担保余额 | 0 万元 | | | | 是否在前期预计额度内 | ☑是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | ☑是 □否 | ...

证券代码：603858 证券简称：步长制药 公告编号：2025-217 山东步长制药股份有限公司 关于公司拟购买安宫牛黄丸药品生产技术相关事宜的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 山东步长制药股份有限公司（以下简称"公司"或"步长制药"）于 2023 年 4 月 14 日召开第四届董事会第三十四次会议，审议通过了《关于公司拟购买安宫牛黄 丸药品生产技术相关事宜的议案》，根据公司发展战略的实际需要，为丰富公司产 品，公司拟以 840 万元受让辽宁汉草堂中药有限公司（以下简称"辽宁汉草堂"） 拥有的安宫牛黄丸药品生产技术。具体内容详见公司 2023 年 4 月 15 日披露于上海 证券交易所网站（www.sse.com.cn）的《关于公司拟购买安宫牛黄丸药品生产技术 相关事宜的公告》（公告编号：2023-056）。 2023 年 4 月 21 日，公司与辽宁汉草堂正式签订了《药品上市许可持有人变更 和药品生产场地变更技术合同》，具体内容详见公司 2023 年 4 月 22 日披露于上海 证券交易 ...

Core Points - Shandong Buchang Pharmaceutical Co., Ltd. announced on November 20, 2025, that its subsidiary, Jinan Buchang Caikan Trading Co., Ltd., has completed the registration of a business address change to optimize its operational management [1][2] - The change was approved during the 33rd meeting of the fifth board of directors on October 20, 2025, and the new registered address is in the High-tech Industrial Development Zone of Laiwu, Jinan, Shandong Province [1] - The subsidiary's registered capital is 1 million yuan, and its business scope includes wholesale of daily necessities, medical protective supplies, and various sales of healthcare products and medical devices [1] Company Information - The new business address is located at Century City, Pengquan Street, Laiwu High-tech Zone, Jinan, Shandong Province [1] - The company aims to enhance the operational efficiency of its subsidiary through this address change [1] - Buchang Pharmaceutical will continue to monitor the subsidiary's business development and comply with relevant legal disclosure obligations [1]

证券代码：603858 证券简称：步长制药 公告编号：2025-216 山东步长制药股份有限公司 关于控股子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 10 月 20 日召开 第五届董事会第三十三次会议，审议通过了《关于控股子公司住所变更的议案》， 公司控股子公司济南步长财淦商贸有限公司（以下简称"步长财淦"）因经营管 理之需要，拟对其住所进行变更。具体内容详见公司 2025 年 10 月 21 日披露于 上海证券交易所网站（www.sse.com.cn）的《关于控股子公司住所变更的公告》 （公告编号：2025-199）。 近日，步长财淦已完成工商变更登记手续，并取得莱芜高新技术产业开发区 市场监督管理局换发的营业执照，变更后的相关信息如下： 名称：济南步长财淦商贸有限公司 类型：其他有限责任公司 法定代表人：周彦丰 注册资本：壹佰万元整 成立日期：2025 年 02 月 14 日 住所：山东省济南市莱芜高新区鹏泉街道世纪城路 1 号 ...

Group 1 - The company held its first extraordinary general meeting of shareholders on November 17, 2025, with no resolutions being rejected [2] - The meeting was legally convened and conducted, with the presence of all directors and supervisors, and was chaired by the board secretary [3][4] - Several resolutions were passed, including the cancellation of the supervisory board and adjustments to the number of directors [4][5][6] Group 2 - The company announced the election of Wu Bing as the employee representative director of the fifth board of directors, effective immediately [9][10] - Wu Bing has been with the company since 2000 and currently serves as the director of the securities department [11] Group 3 - The company plans to invest in a new joint venture, Nanjing Keyinno Biotechnology Co., Ltd., with a registered capital of 2 million yuan, where the company’s subsidiary will hold an 11.11% stake [12][14] - The investment will not change the scope of the company's consolidated financial statements and does not require shareholder approval [14][18] - The joint venture aims to enhance business development and leverage the strengths of all parties involved [28]

Group 1 - The company held a staff representative meeting on November 17, 2025, where Mr. Wu Bing was elected as the staff representative director for the fifth board of directors [1][3] - The new board will consist of Mr. Wu Bing and four other directors elected at the first extraordinary shareholders' meeting in 2025, ensuring that the number of directors who are also senior management or staff representatives does not exceed half of the total board members [1][3] - The election process complied with relevant laws and regulations, and the company confirmed the accuracy and completeness of the announcement [1][4] Group 2 - The first extraordinary shareholders' meeting of 2025 was held on November 17, 2025, with all resolutions passed without any objections [5][6] - The meeting was chaired by the board secretary, and all current directors and supervisors attended, confirming the legality and validity of the meeting [6][9] - Several resolutions were passed, including the cancellation of the supervisory board and adjustments to the number of directors, all requiring a two-thirds majority for special resolutions [7][8] Group 3 - The company announced plans for its subsidiary, Zhejiang Huapai, to invest in a new joint venture, Nanjing Keyinno Biotechnology Co., Ltd., with a registered capital of 2 million yuan [12][13] - Zhejiang Huapai will hold an 11.11% stake in the new company, contributing 222,200 yuan, while other partners will hold the remaining shares [15][16] - This investment is aimed at enhancing business development and research capabilities, aligning with the company's strategic goals without affecting its consolidated financial statements [20]

Core Viewpoint - On November 17, 2025, the company held a staff representative meeting where Mr. Wu Bing was elected as the employee representative director of the fifth board of directors [1] Group 1 - The company announced the date of the staff representative meeting as November 17, 2025 [1] - Mr. Wu Bing was elected to the board during this meeting [1]

Core Viewpoint - The company, Buchang Pharma, is expanding its business through a joint investment with several partners to establish a new company, enhancing its research capabilities and market competitiveness [1] Group 1: Investment and Partnership - Zhejiang Huapai, a subsidiary of Buchang Pharma, plans to invest in a new company alongside Hefei Keyinou Biotechnology Co., Jiangsu Industrial Technology Research Institute, and Hefei Kaisaisi Enterprise Management Partnership [1] - The registered capital of the joint venture is 2 million yuan, with Zhejiang Huapai contributing 222,200 yuan [1] Group 2: Strategic Development - The collaboration aims to leverage the strengths of each party, fostering stable partnerships and strategic alliances [1] - This investment aligns with national macro strategies and industry directions, supporting the company's strategic development needs [1] - The project is expected to enhance the research capabilities of both the company and Zhejiang Huapai, laying a solid foundation for future growth [1]

山东步长制药股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-215 山东步长制药股份有限公司董事会 2025 年 11 月 18 日 附：职工代表董事简历 吴兵先生，男，出生于 1967 年 7 月 12 日，中国国籍，无境外永久居留权。 2000 年加入公司，历任公司财务部副科长、证券部部长、职工代表监事等职务； 现任公司证券部总监、证券事务代表等职务。 吴兵先生未持有公司股份，与公司的董事、高级管理人员、实际控制人及持 股 5%以上的股东不存在关联关系。 根据《公司法》等法律法规、规范性文件及《公司章程》的相关规定，山东 步长制药股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日召开职工代 表大会。会议选举吴兵先生担任公司第五届董事会职工代表董事（简历附后）， 任期自职工代表大会审议通过之日起至公司第五届董事会任期届满之日止。 本次选举职工代表董事工作完成后，吴兵先生将与第五届董事会现任成员以 及公司 ...